New Parkinson's drug candidate PDM608 begins first human safety tests
NCT ID NCT05950906
First seen Nov 18, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This early-phase study tested the safety and tolerability of a new drug called PDM608 in 64 healthy adults. The goal was to see if the drug is safe enough to study further in people with Parkinson's disease. Participants received either PDM608 or a placebo, and researchers monitored for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Quotient Sciences-Miami, Inc
Miami, Florida, 33126, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PDM608
What this could lead to
If successful, this could lead to a new treatment option for Parkinson's disease.
What could go wrong
This is a very early Phase 1 trial in healthy volunteers, not people with Parkinson's. It only tests safety and dosing, not whether the drug works for the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.